Skip to main content
Premium Trial:

Request an Annual Quote

OncoMed Licenses MorphoSys HuCal Library to Help Develop Cancer Therapies

NEW YORK, June 7 (GenomeWeb News) - OncoMed Pharmaceuticals has licensed an antibody library from MorphoSys to research and develop therapeutic antibodies for the treatment of several cancers, the companies said today.


According to the terms of the agreement, OncoMed will gain access to MorphoSys' HuCal Gold library for two years in exchange for an up-front payment and annual user fees, the companies said.


The firms did not disclose additional financial details.


OncoMed will use the library to develop therapies against cancer stem cells in breast, lung, colon, prostate, and other cancers, the company said.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.